Harvard Bioscience Inc. (HBIO) Shares Down 3.7%
Shares of Harvard Bioscience Inc. (NASDAQ:HBIO) dropped 3.7% during mid-day trading on Friday . The stock traded as low as $2.58 and last traded at $2.60, with a volume of 91,040 shares changing hands. The stock had previously closed at $2.70.
Separately, Zacks Investment Research downgraded shares of Harvard Bioscience from a “hold” rating to a “sell” rating in a research report on Thursday, May 5th.
The stock’s 50 day moving average is $2.82 and its 200 day moving average is $2.98. The stock’s market capitalization is $89.21 million.
Harvard Bioscience (NASDAQ:HBIO) last announced its quarterly earnings data on Thursday, July 28th. The company reported $0.03 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.03. The business had revenue of $26.10 million for the quarter, compared to analyst estimates of $26.60 million. On average, analysts forecast that Harvard Bioscience Inc. will post $0.16 EPS for the current fiscal year.
Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of specialized products, apparatus and scientific instruments. The Company’s products are used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories across the world.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.